What European Medtechs Should Know About The US Patent System

Five critical factors that can determine whether groundbreaking medtech innovations are protected in the US.

As noted in the first article in our Medtech Coming to America series, "US Emerging as Top Global Medtech Destination," perceived regulatory advantages are prompting European medtechs to enter the US market earlier in their life cycles than in the past. But succeeding in the US requires understanding a patent system that has several key differences from the European one.

For medtech companies, intellectual property (IP) is often their most valuable asset — directly influencing market exclusivity, investor confidence, and long-term competitive positioning. A well-planned patent strategy can mean the difference between market leadership and missed opportunity. Companies that don't know how to navigate the US system may fail to obtain adequate patent protection, incur unexpected costs, or overlook strategic advantages unique to the US market.